Poly(ADP‐ribose) polymerase (PARP) inhibitors for the ...
Studies on PARPi in ovarian cancer show improved progression-free survival (PFS) but unclear overall survival (OS) benefits. Quality of life (QoL) data is heterogeneous, with some studies indicating maintained QoL during treatment. Serious adverse events are more common with PARPi, impacting QoL. Evidence is most robust for olaparib, with less data for other PARPis. Long-term follow-up is needed for clearer OS outcomes.
Reference News
Studies on PARPi in ovarian cancer show improved progression-free survival (PFS) but unclear overall survival (OS) benefits. Quality of life (QoL) data is heterogeneous, with some studies indicating maintained QoL during treatment. Serious adverse events are more common with PARPi, impacting QoL. Evidence is most robust for olaparib, with less data for other PARPis. Long-term follow-up is needed for clearer OS outcomes.